Compare Global Payments Inc (GPN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Global Payments Inc trades at $82.55 (market cap $21.46B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: Global Payments Inc is far larger — about 2.1× State Street SPDR S&P Biotech ETF's market cap, and Global Payments Inc pays a 1.23% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global Payments Inc for 50 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GPN | XBI | |
|---|---|---|
Market Cap | $21.46B | $10.11B |
Volume | 1,482,600 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $94.83 | $169.55 |
52-Week Low | $62.47 | $104.99 |
Typical Hold Time | 50 Days | 38 Days |
Enterprise Value | $39.60B | — |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $82.20, up 1.38% with neutral technical signals. The stock shows strong earnings momentum with three consecutive quarterly beats, though faces profitability challenges with negative net margins. Recent developments include the Genius platform rollout and Worldpay integration driving growth potential. Valuation metrics show a P/E of 38.43 and P/B below book value at 0.93, while analyst consensus remains bullish with a $102.75 price target.
Investment outlook balances growth catalysts from digital payment expansion against rising costs and competitive pressures. The 24% upside to consensus target offers potential reward, but investors must weigh debt levels increasing to 41.57% debt-to-asset ratio and projected 2026 net loss against strategic initiatives. Near-term performance hinges on Q3 earnings delivery and Genius adoption metrics.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
